NCT07217067View on ClinicalTrials.gov

A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

August 20, 2027

Study Completion Date

August 20, 2027

Conditions
Atrial Fibrillation
Interventions
DRUG

PKN605

PKN605 is an oral formulation

OTHER

Placebo

Matching placebo

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY